Application of traditional Chinese medicine composition in preparation of medicine for treating, relieving or preventing gastrointestinal dysfunction
Through the extraction and preparation of traditional Chinese medicine compositions, the treatment problem of gastrointestinal dysfunction has been solved, the treatment effect has been significantly improved, the gastric emptying rate has been reduced, the small intestine propulsion rate has been increased, the symptoms have been alleviated, and the clinical application value has been achieved.
Patent Information
- Application Number
- CN202410244858.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2024-03-04
- Publication Date
- 2024-11-26
AI Technical Summary
Gastrointestinal dysfunction is a complex disease that is difficult to effectively treat and prevent in the prior art, especially its high incidence and recurrent problems have serious impacts on health and quality of life.
Provided is a traditional Chinese medicine composition, including Magnolia officinalis, roasted betel nut, simmered berry fruit, ephedra, bitter almond, ginger, patchouli, perilla, atractylodes, poria cocos, atractylodes, gypsum, scorched hawthorn, scorched Liushenqu, scorched malt , Dilong, Xu Changqing, Mianma Guanzhong and cypress are extracted, filtered, concentrated and dried by reflux of water to prepare into drugs for treatment, alleviation or prevention of gastrointestinal dysfunction. Dosage forms include oral dosage forms or topical dosage forms Pharmaceutical preparations.
It significantly improved the treatment effect of gastrointestinal dysfunction, significantly reduced the gastric emptying rate of mice and increased the small intestine propulsion rate, relieved symptoms such as abdominal pain and abdominal distension, and has clinical promotion value.
Smart Images

Figure BDA0004726735070000051 
Figure BDA0004726735070000061 
Figure BDA0004726735070000071
Abstract
Description
[0001] This application claims the priority of the Chinese patent application filed with the China Patent Office on May 26, 2023, with application number 2023106124219 and invention name “Application of Chinese herbal medicine compositions in the preparation of drugs for treating, alleviating or preventing gastrointestinal dysfunction”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The present invention relates to the technical field of traditional Chinese medicines, and in particular to the use of a traditional Chinese medicine composition in preparing medicines for treating, alleviating or preventing gastrointestinal dysfunction. Background Art
[0003] Functional gastrointestinal disorders (FGIDs) are diseases of brain-gut interaction. It is a group of diseases classified according to any combination of the following related gastrointestinal symptoms: motility disorders, visceral hypersensitivity, changes in mucosal and immune function, changes in intestinal microbial populations, and changes in central nervous system (CNS) function. The incidence rate is high, accounting for about 40% to 60% of gastrointestinal diseases, and it is increasing year by year. In addition, the recurrence rate is high, which is more common in young and middle-aged people, seriously affecting people's physical health and quality of life. It is also called gut-brain interaction abnormality. It is a functional gastrointestinal disease with chronic or recurrent gastrointestinal symptoms as the main manifestation but no organic changes. Its onset is related to the enteric-brain nervous system, intestinal flora-gut-brain axis, psychosocial factors and various physiological process abnormalities (motility disorders, changes in mucosal barriers and immune function, visceral hypersensitivity, dietary factors), etc. Summary of the invention
[0004] In order to solve the above technical problems, the technical problem to be solved by the present invention is to provide an application of a Chinese medicine composition in the preparation of a drug for treating, alleviating or preventing gastrointestinal dysfunction.
[0005] Specifically, the present invention provides an application of a traditional Chinese medicine composition in the preparation of a drug for treating, alleviating or preventing gastrointestinal dysfunction. The traditional Chinese medicine composition comprises, by weight: 1-100 parts of Magnolia officinalis, 1-100 parts of charred Areca catechu, 1-100 parts of stewed Tsaoko fruit, 1-100 parts of Ephedra, 1-100 parts of Bitter Apricot, 1-100 parts of Notopterygium wilfordii, 1-100 parts of ginger, 1-100 parts of Patchouli, 1-100 parts of Cyperus rotundus, 1-100 parts of Atractylodes macrocephala, 1-160 parts of Poria cocos, 1-120 parts of Atractylodes macrocephala, 1-100 parts of Gypsum, 1-100 parts of charred Crataegus pinnatifida, 1-100 parts of charred Liu Shenqu, 1-100 parts of charred malt, 1-100 parts of Pheretima, 1-100 parts of Cynanchum cyrtonema, and 1-100 parts of Lemongrass.
[0006] The application method may be any method that is beneficial to improving the corresponding symptoms of the patient, including treatment, alleviation or prevention.
[0007] Furthermore, the Chinese medicine composition comprises, by weight: 10-80 parts of Magnolia officinalis, 10-80 parts of scorched Areca catechu, 10-80 parts of simmered Tsaoko fruit, 10-60 parts of Ephedra sinica, 10-60 parts of Bitter Apricot, 10-80 parts of Notopterygium wilfordii, 10-60 parts of Ginger, 10-80 parts of Patchouli, 10-60 parts of Cyperus rotundus, 10-80 parts of Atractylodes macrocephala, 10-160 parts of Poria cocos, 10-120 parts of Atractylodes macrocephala, 10-80 parts of Gypsum, 10-50 parts of scorched Crataegus pinnatifida, 10-80 parts of scorched Liu Shenqu, 10-60 parts of scorched malt, 10-80 parts of Pheretima, 10-80 parts of Cynanchum cyrtonema, 10-60 parts of Semen Lepidii.
[0008] Preferably, the Chinese medicine composition comprises, by weight: 30-50 parts of Magnolia officinalis, 20-30 parts of scorched Areca catechu, 30-50 parts of stewed Tsaoko fruit, 20-30 parts of Ephedra sinica, 20-30 parts of Bitter Apricot, 30-50 parts of Notopterygium wilfordii, 30-50 parts of Ginger, 30-50 parts of Patchouli, 20-30 parts of Cyperus rotundus, 30-50 parts of Atractylodes macrocephala, 120-150 parts of Poria cocos, 80-100 parts of Atractylodes macrocephala, 30-50 parts of Gypsum, 20-30 parts of scorched Crataegus pinnatifida, 30-50 parts of scorched Liu Shenqu, 20-30 parts of scorched malt, 30-50 parts of Pheretima, 30-50 parts of Cynanchum wilfordii, 20-30 parts of Cyperus rotundus, and 30-50 parts of Lemongrass seeds.
[0009] Preferably, the Chinese medicine composition comprises, by weight: 50 parts of Magnolia officinalis, 30 parts of scorched betel nut, 30 parts of stewed tsaoko fruit, 20 parts of ephedra, 30 parts of bitter almond, 50 parts of Notopterygium wilfordii, 50 parts of ginger, 50 parts of patchouli, 30 parts of Cyperus rotundus, 50 parts of Atractylodes macrocephala, 150 parts of Poria cocos, 100 parts of Atractylodes macrocephala, 50 parts of gypsum, 30 parts of scorched hawthorn, 30 parts of scorched Liu Shenqu, 30 parts of scorched malt, 50 parts of earthworm, 50 parts of Cynomorium wilfordii, 30 parts of Cynomorium fortunei, and 50 parts of Lemongrass seeds.
[0010] The above-mentioned Chinese medicine composition can be directly ground into powder by raw materials, or can be an extract or other forms prepared by conventional means.
[0011] Preferably, the preparation method of the Chinese medicine composition is:
[0012] Mix Magnolia officinalis, scorched areca nut, stewed tsaoko fruit, ephedra, bitter almond, notopterygium wilfordii, ginger, patchouli, perilla, atractylodes, Poria, atractylodes, gypsum, scorched hawthorn, scorched Liushenqu, scorched malt, earthworm, Cynanchum chinense, Cynomorium fortunei, and Lemongrass seed, add water for reflux extraction, filter, concentrate and dry the extract to obtain the above-mentioned Chinese medicine composition.
[0013] Preferably, the water-adding reflux extraction is:
[0014] Add water and reflux and extract twice. The first time, add 6 times of water and extract for 1.5 hours. The second time, add 4 times of water and extract for 1.0 hour.
[0015] Preferably, the extract is filtered, concentrated and dried as follows:
[0016] The extracts are combined, filtered, and the filtrate is concentrated to a relative density of 1.10-1.15, centrifuged, and the filtrate is vacuum dried and spray dried for pulverization.
[0017] In some specific embodiments of the present invention, after the spray drying and pulverization, the process further comprises: adding sucralose and dextrin, mixing well, and obtaining granules.
[0018] Specifically, the dosage form of the gastrointestinal dysfunction drug includes an oral dosage form, an injection dosage form or an external administration preparation.
[0019] The dosage forms of the drug of the present invention include but are not limited to decoctions, granules, capsules, tablets, oral liquids, pills, tinctures, syrups, gels, sprays or injections, etc. After weighing the raw materials according to the proportion, the present invention adds pharmaceutically acceptable excipients such as fillers, disintegrants, lubricants, suspending agents, adhesives, sweeteners, flavoring agents, preservatives, bases, etc., and prepares according to conventional production methods in the pharmaceutical field to prepare the above-mentioned conventional dosage forms acceptable to pharmacy.
[0020] In some specific embodiments, the gastrointestinal dysfunction is gastrointestinal dysfunction caused by rhubarb or gastrointestinal dysfunction caused by dexamethasone.
[0021] The dosage of the above-mentioned traditional Chinese medicine composition is preferably 6 to 40 g / Kg, more preferably 12 to 38 g / Kg.
[0022] Compared with the prior art, the present invention provides an application of a Chinese medicine composition in the preparation of a drug for treating, alleviating or preventing gastrointestinal dysfunction. The test results show that the Chinese medicine composition can significantly increase the small intestinal propulsion rate of mice and rats caused by gastrointestinal dysfunction, and can significantly reduce the gastric emptying rate of mice and rats, and has a good therapeutic effect on gastrointestinal dysfunction; it can significantly improve the therapeutic effect, and the patient's abdominal pain time, abdominal pain frequency, abnormal defecation characteristics, and abdominal distension symptom relief rate are also significantly improved, which has clinical promotion value. DETAILED DESCRIPTION
[0023] To further illustrate the present invention, the application of the Chinese medicine composition provided by the present invention in preparing a medicine for treating, alleviating or preventing gastrointestinal dysfunction is described in detail below in conjunction with examples.
[0024] The following experiments, if no specific conditions are specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The APIs or excipients, reagents or instruments used, if the manufacturer is not specified, are all conventional products that can be purchased commercially. Unless otherwise specified, all percentages, ratios, proportions or parts are by weight.
[0025] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention.
[0026] Example 1
[0027] Preparation of composite granules
[0028] The Chinese medicine composition of this embodiment is prepared from the following raw materials: 50 grams of Magnolia officinalis, 30 grams of scorched betel nut, 30 grams of stewed tsaoko, 20 grams of ephedra, 30 grams of bitter almond, 50 grams of Notopterygium wilfordii, 50 grams of ginger, 50 grams of patchouli, 30 grams of Cyperus rotundus, 50 grams of Atractylodes macrocephala, 150 grams of Poria, 100 grams of Atractylodes macrocephala, 50 grams of gypsum, 30 grams of scorched hawthorn, 30 grams of scorched Liu Shenqu, 30 grams of scorched malt, 50 grams of earthworm, 50 grams of Cynomorium fortunei, 30 grams of Cynomorium cyrtonema, and 50 grams of Lemongrass.
[0029] The Chinese medicine composition is prepared according to the following method:
[0030] Take the above medicinal materials, add water and reflux extract twice, add 6 times water for the first time, extract for 1.5 hours, add 4 times water for the second time, extract for 1.0 hours, combine the extracts, filter, concentrate the filtrate to a relative density of 1.10-1.15, centrifuge and filter, vacuum dry the filtrate, spray dry and crush to obtain an intermediate composition, add sucralose and dextrin, mix well, and obtain granules.
[0031] Pharmacological tests
[0032] The test drug of the present invention is obtained according to the preparation method of Example 1 of the present invention.
[0033] Experimental Example 1 Effect of rhubarb on gastrointestinal dysfunction in rats
[0034] Experimental Materials:
[0035] Animals: SD rats, SPF grade, half male and half female, a total of 60 rats, weighing 180-200 g. Purchased from Nantong University, license number: SCXK (Beijing) 2019-0001.
[0036] Medicine: Rhubarb, Pizhou Kangmei Chinese Medicinal Materials Planting Professional Cooperative, specification: 20kg / bag.
[0037] Positive control drug: Kaiwei Jianpi Pills, Li Shizhen Pharmaceutical Co., Ltd., specification: 1 gram per 10 pills.
[0038] Test drug: the granules of Example 1, provided by Jiangsu Kangyuan Pharmaceutical Co., Ltd.
[0039] Reagents: Gum Arabic, Shanghai Shenggong, specification: 100g / bottle, batch number: GB25BA0025. Carbon powder, Shanghai Shenggong, specification: 1kg / bag, batch number: H302BA0013. Chloral hydrate, Shanghai Sinopharm Chemical Reagent Co., Ltd., specification: 250g / bottle, batch number: 20150629. Sodium chloride solution, Shijiazhuang Siyao Co., Ltd., specification: 500mL / bottle, batch number: 1803193205.
[0040] Instruments: Electronic balance, METTLER TOLEOD, model: MS1003S101. Animal weighing scale, Kagawa, model: ACX-SC-DA.
[0041] Experimental methods
[0042] SD rats, half male and half female, about 180-200g, were randomly divided into 6 groups by body weight, 10 in each group. After grouping, except the normal control group, the remaining rats were gavaged with 2g / mL rhubarb decoction (10mL / kg), administered twice a day, and modeled for 7 days in a row. Starting on the 8th day, Chinese medicine composition granule different dose groups of the present invention (6.48g crude drug / kg, 12.96g crude drug / kg, 25.92g crude drug / kg) and positive drug group, each group was gavaged with corresponding drugs by 10ml / kg dosage respectively. Blank control group and model control group were gavaged with pure water of the same volume respectively, administered once a day, for 7 days in a row.
[0043] Detection index: ① Gastric emptying measurement: fasting but not water for 12 hours on the day of the last administration. Gastric emptying measurement was performed the next day. Solid paste (10% activated carbon powder, 10% gum arabic) was diluted with warm water and gavaged to each rat at 10 mL / kg body weight. The mass of semisolid injected was recorded. After gavage for 10 minutes, the rat was anesthetized with 10% chloral hydrate and the stomach of the rat was quickly removed. The weight of the stomach filled with semisolid W1 was recorded, cut open along the greater curvature of the stomach, and then the semisolid was cleaned with pure water, and the weight of the empty stomach W2 was recorded. The gastric residual rate was calculated according to the following formula: gastric residual rate (%) = (W1-W2) / V×100%. ② While removing the rat's stomach, the small intestine was quickly cut and straightened naturally. The distance from the pyloric sphincter to the front edge of the carbon powder was measured as the distance of pigment advancement in the small intestine; the total length from the pyloric sphincter to the ileocecal part was taken as the total length of the small intestine, and the small intestine advancement rate (%) was calculated.
[0044] Experimental Results
[0045] The results showed that compared with the normal group, the small intestinal propulsion rate of the model control group rats was significantly reduced (P < 0.05), and the gastric residual rate was significantly increased ((P < 0.01)), indicating that the model was successfully established. The small intestinal propulsion rate and gastric residual rate of the medium and high dose groups of the Chinese medicine composition and the positive drug group were significantly improved compared with the model group (P < 0.01, P < 0.05), indicating that the Chinese medicine composition of the present invention can significantly improve the changes in gastrointestinal dysfunction in rats caused by rhubarb decoction.
[0046] The results are shown in Table 1.
[0047] Table 1 Effects on small intestinal propulsion rate and gastric residual rate in rats
[0048]
[0049]
[0050] Note: Compared with the normal control group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01.
[0051] Experimental Example 2 Effect of dexamethasone on gastrointestinal dysfunction in mice
[0052] Test Materials:
[0053] Animals: ICR mice, SPF grade, weighing 10-12 g, provided by Nantong University, experimental animal production license: SCXK (Su) 2019-0001.
[0054] Drug: Dexamethasone acetate tablets, Chenxin Pharmaceutical Co., Ltd., batch number: 190817201.
[0055] Positive control drug: Kaiwei Jianpi Pills, Li Shizhen Pharmaceutical Co., Ltd., specification: 1 gram per 10 pills.
[0056] Test drug: the granules of Example 1, provided by Jiangsu Kangyuan Pharmaceutical Co., Ltd.
[0057] Reagent: Gum Arabic, Shanghai Shenggong, specification: 100g / bottle, batch number: GB25BA0025.
[0058] Carbon powder, Shanghai Shenggong, specification: 1kg / bag, batch number: H302BA0013.
[0059] Sodium chloride solution, Shijiazhuang Siyao Co., Ltd., specification: 500mL / bottle, batch number: 1803193205.
[0060] Instruments: Electronic balance, METTLER TOLEOD, model: MS1003S101. Animal weighing scale, Kagawa, model: ACX-SC-DA.
[0061] Experimental methods
[0062] 66 ICR mice, 30 females and 36 males, weighing 9-11g, were selected and randomly divided into 6 groups according to body weight, with 11 mice in each group. The 6 groups were normal control group, model group, low, medium and high dose groups of Chinese medicine composition (9.36g crude drug / kg, 18.72g crude drug / kg, 37.44g crude drug / kg), and positive control group. After grouping, each group was gavaged once a day according to the set dose according to the volume of 20mL / kg. Dexamethasone suspension was gavaged 0.5h after administration on the first day, and the blank control group was given an equal amount of solvent. The drugs were administered for 5 consecutive days. The animals were fasted for 18-24h before the last administration. After the last administration and the administration of dexamethasone 1h (except the normal control group), the semi-solid paste was gavaged at a volume of 20mL / kg. After 10min, the mice were killed for index detection.
[0063] Detection index: ① Gastric emptying measurement: Use warm water to make solid paste (10% activated carbon powder, 10% gum arabic), and gavage each rat at 20mL / kg body weight, record the mass of the semi-solid injected, and quickly remove the mouse stomach 10 minutes after gavage. Record the weight of the stomach filled with semi-solid W1, cut the stomach along the greater curvature, and then clean the semi-solid, record the weight of the empty stomach W2, and calculate the gastric residual rate according to the following formula: gastric residual rate (%) = (W1-W2) / V×100%. . ② While removing the mouse stomach, quickly cut the small intestine, straighten it naturally, measure the distance from the pyloric sphincter to the forefront of the carbon powder as the distance of the pigment advancing in the small intestine; the total length from the pyloric sphincter to the ileocecal part is the total length of the small intestine, and calculate the small intestine advancement rate (%).
[0064] Experimental results:
[0065] Compared with the normal group, the small intestinal propulsion rate of mice in the model control group was significantly reduced (P < 0.05), and the gastric residual rate was significantly increased ((P < 0.01)), indicating that the model was successfully established. The small intestinal propulsion rate and gastric residual rate of the medium and high dose groups of the Chinese medicine composition and the positive drug group were significantly improved compared with the model group (P < 0.01, P < 0.05), indicating that the Chinese medicine composition of the present invention can significantly improve the changes in gastrointestinal dysfunction in mice caused by dexamethasone.
[0066] The results are shown in Table 2.
[0067] Table 2 Effects on small intestinal propulsion rate and gastric residual rate in mice
[0068]
[0069] Note: Compared with the normal control group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01.
[0070] The above examples show that the composition of the present invention can significantly increase the small intestinal propulsion rate of mice and rats caused by gastrointestinal dysfunction, and can significantly reduce the gastric emptying rate of mice and rats, indicating that the composition of the present invention has a good therapeutic effect on gastrointestinal dysfunction.
[0071] The above embodiments are only used to help understand the method and core idea of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. Use of a Chinese medicine composition in the preparation of a drug for treating, alleviating or preventing gastrointestinal dysfunction, the Chinese medicine composition comprising, by weight: 1-100 parts of Magnolia officinalis, 1-100 parts of scorched betel nut, 1-100 parts of stewed grass fruit, 1-100 parts of ephedra, 1-100 parts of bitter almond, 1-100 parts of Notopterygium wilfordii, 1-100 parts of ginger, 1-100 parts of patchouli, 1-100 parts of Cyperus rotundus, 1-100 parts of Atractylodes macrocephala, 1-160 parts of Poria cocos, 1-120 parts of Atractylodes macrocephala, 1-100 parts of gypsum, 1-100 parts of scorched hawthorn, 1-100 parts of scorched Liu Shenqu, 1-100 parts of scorched malt, 1-100 parts of earthworms, 1-100 parts of Cynanchum chinense, 1-100 parts of Cyperus rotundus, and 1-100 parts of Lepidium chinense.
2. The use according to claim 1, characterized in that: The Chinese medicine composition comprises, by weight, 10-80 parts of Magnolia officinalis, 10-80 parts of scorched betel nut, 10-80 parts of stewed tsaoko, 10-60 parts of ephedra, 10-60 parts of bitter almond, 10-80 parts of notopterygium wilfordii, 10-60 parts of ginger, 10-80 parts of patchouli, 10-60 parts of perilla, 10-80 parts of atractylodes, 10-160 parts of Poria, 10-120 parts of Atractylodes macrocephala, 10-80 parts of gypsum, 10-50 parts of scorched hawthorn, 10-80 parts of scorched six-spirited herb, 10-60 parts of scorched malt, 10-80 parts of earthworm, 10-80 parts of Cynanchum chinense, 10-60 parts of Cynomorium fortunei, and 10-80 parts of Lepidium chinense.
3. The use according to claim 2, characterized in that: The Chinese medicine composition comprises, by weight, 30-50 parts of magnolia bark, 20-30 parts of burnt betel nut, 30-50 parts of stewed tsaoko, 20-30 parts of ephedra, 20-30 parts of bitter almond, 30-50 parts of notopterygium, 30-50 parts of ginger, 30-50 parts of patchouli, 20-30 parts of perilla, 30-50 parts of atractylodes, 120-150 parts of tuckahoe, 80-100 parts of atractylodes, 30-50 parts of gypsum, 20-30 parts of burnt hawthorn, 30-50 parts of burnt six-spirit song, 20-30 parts of burnt malt, 30-50 parts of earthworm, 30-50 parts of cynanchum chinense, 20-30 parts of cyperus rotundus, and 30-50 parts of scutellaria baicalensis. Preferably, it comprises: 50 parts of Magnolia officinalis, 30 parts of scorched areca nut, 30 parts of stewed tsaoko fruit, 20 parts of ephedra, 30 parts of bitter almond, 50 parts of Notopterygium wilfordii, 50 parts of ginger, 50 parts of patchouli, 30 parts of Cyperus rotundus, 50 parts of Atractylodes macrocephala, 150 parts of Poria cocos, 100 parts of Atractylodes macrocephala, 50 parts of gypsum, 30 parts of scorched hawthorn, 30 parts of scorched Liu Shenqu, 30 parts of scorched malt, 50 parts of earthworm, 50 parts of Cynomorium macrostemon, 30 parts of Cynomorium fortunei, and 50 parts of Lemongrass seeds.
4. The use according to claim 1, characterized in that: The dosage form of the gastrointestinal dysfunction drug includes an oral dosage form, an injection dosage form or an external administration preparation.
5. The use according to claim 4, characterized in that: The dosage form of the gastrointestinal dysfunction drug includes decoction, granules, capsules, tablets, oral liquid, pills, tincture, syrup, gel, spray or injection.
6. The use according to any one of claims 1 to 3, characterized in that: The preparation method of the Chinese medicine composition is: Mix Magnolia officinalis, scorched areca nut, stewed tsaoko fruit, ephedra, bitter almond, notopterygium wilfordii, ginger, patchouli, perilla, atractylodes, Poria, atractylodes, gypsum, scorched hawthorn, scorched Liushenqu, scorched malt, earthworm, Cynanchum chinense, Cynomorium fortunei, and Lemongrass seed, add water for reflux extraction, filter, concentrate and dry the extract to obtain the above-mentioned Chinese medicine composition.
7. The use according to claim 6, characterized in that: The water-adding reflux extraction is: Add water and reflux and extract twice. The first time, add 6 times of water and extract for 1.5 hours. The second time, add 4 times of water and extract for 1.0 hour.
8. The use according to claim 6, characterized in that: The extract is filtered, concentrated and dried to obtain: The extracts are combined, filtered, and the filtrate is concentrated to a relative density of 1.10-1.15, centrifuged, and the filtrate is vacuum dried and spray dried for pulverization.
